Advertising disclosure: we may earn a commission when you buy through links on this site. How we make money

HomeTrials › NCT07505303

Obesity & weight · Phase 2 · Opening soon

MIST (Metabolic Intervention With Semaglutide and THR-β Therapy) Trial

NCT07505303 · Sponsor: Eccogene

What this trial means for you

This study is opening soon at 15 US sites. It's studying ECC4703, Placebo, Semaglutide for adult obesity, weight management.

Who can joinAll sexes, 18 Years – 75 Years
Healthy volunteersAccepted
What you'd takeECC4703, Placebo, Semaglutide
Study length~8 months overall
Planned participants160
TypeInterventional (you receive treatment)

What participants typically get: study medication (or placebo, if the trial uses one) and study-related medical care at no cost, plus close monitoring. Compensation for time and travel varies by study — ask the site. Note that in many trials you can't choose your treatment group, and some participants receive a placebo.

The study, in the sponsor's words

The primary objective of this trial is to evaluate the effect of oral ECC4703 on body weight reduction and in a sub-study on liver fat content as assessed by change in magnetic resonance imaging proton density fat fraction (MRI-PDFF) at Week 20.

Can you join? The exact criteria

Below is the verbatim eligibility text from the registry — bring it to your doctor; it's written for clinicians, and your own clinician is the right person to interpret it with you.

Full eligibility criteria (for you and your doctor)

Inclusion Criteria: 1. Capable of providing written informed consent and complying with all trial procedures. 2. Willing to comply with contraception requirements (as applicable to males and females of childbearing potential). 3. Obese with BMI ≥30 kg/m\^2 and stable body weight within 6 months prior to screening. 4. HbA1c ≤6.5%. 5. Estimated glomerular filtration rate (eGFR) ≥60 mL/min/1.73 m\^2 (per CKD-EPI 2021 formula). 6. If participant consents to enter the imaging substudy, has liver fat content by MRI-PDFF \>8% at baseline (Week 9). Exclusion Criteria: 1. History or current diagnosis of type 1 or type 2 diabetes mellitus. 2. Weight change \>5% of total body weight within 6 months prior to screening or planned initiation of a weight loss program or use of weight-altering medication. 3. Obesity induced by endocrine disorders such as Cushing's syndrome or monogenic or syndromic obesity such as Prader-Willi syndrome. 4. Use of GLP-1 agonist treatment within the last 6 months prior to screening. 5. History or current evidence of a pituitary disorder. 6. Have current treatment with or history (within 3 months prior to screening) of treatment with medications that may cause significant weight gain. 7. ALT or AST \>1.5×ULN, or ALP \>1.5×ULN at screening. 8. Documented evidence or clinical signs/symptoms of advanced liver disease including liver cirrhosis, portal hypertension, or hepatic decompensation. 9. History of significant alcohol consumption for \>3 consecutive months within a year prior to screening. 10. Current or past therapy with THR-β agonists (eg, resmetirom). 11. Active untreated hyperthyroidism or hyperthyroidism currently treated with antithyroid medications including methimazole or propylthiouracil. 12. Clinically significant thyroid dysfunction including uncontrolled hypothyroidism or hyperthyroidism. 13. History of bariatric surgery, fitting of a weight loss device, or intestinal bypass surgery within 5 years prior to screening. 14. History of major surgery within 8 weeks prior to screening. 15. Clinically relevant acute or chronic medical condition or unstable disease of the cardiovascular, gastrointestinal, hepatic, renal, endocrine, pulmonary, neurologic, psychiatric, immune or dermatologic system.

Study sites by state

Alabama

  • Central Research Associates - Flourish - PPDS — Birmingham

California

  • Anaheim Clinical Trials LLC - Anaheim - CenExel - PPDS — Anaheim
  • Collaborative Neuroscience Network - Los Alamitos- CenExel - PPDS — Los Alamitos

Florida

  • AES - DRS - Optimal Research Florida - Melbourne — Melbourne
  • ForCare Clinical Research - CenExel FCR - PPDS — Tampa

Georgia

  • Atlanta Center for Medical Research - CenExel ACMR - PPDS — Atlanta
  • iResearch Atlanta - CenExel - PPDS — Decatur

Minnesota

  • AES - DRS - Synexus Clinical Research US, Inc. - Richfield - Minneapolis — Richfield

Nebraska

  • Velocity Clinical Research (3345 N 107th St) - Omaha - Nebraska - PPDS — Omaha

North Carolina

  • Velocity Clinical Research - Durham - PPDS — Durham

Ohio

  • Velocity Clinical Research - Cincinnati (Springdale) - Ohio - PPDS — Cincinnati

Rhode Island

  • Velocity Clinical Research - Providence - PPDS — East Greenwich

Texas

  • Velocity Clinical Research - Dallas - PPDS — Dallas
  • AES - DRS - Synexus Clinical Research US, Inc. - San Antonio — San Antonio
  • Flourish Research - San Antonio - PPDS — San Antonio

View the official record on ClinicalTrials.gov →

Verify before you act. Medical disclaimer: content on this site is for informational purposes only and is not medical advice. GLP-1 medications are prescription drugs; always consult a licensed healthcare provider about eligibility, risks, and benefits. Trial details and enrollment status change frequently — always verify on the official registry and talk to your own clinician before contacting a study site. This page was generated from registry data and is not affiliated with the study sponsor.

Follow this trial

Get an email when our monthly digest covers enrollment changes and results for trials like this one.

Newsletter signup launches soon. (Site owner: set PUBLIC_BUTTONDOWN_USERNAME in .env to activate this form.)

Keep researching on StudyBackedHealth